Bausch + Lomb Appoints Thomas J. Appio as Interim CEO; Expects to Raise 2026 Guidance

Bausch + Lomb and parent company Bausch Health announced the appointment of Thomas J. Appio as interim chief executive officer, effective immediately. Appio, who has served as Bausch Health CEO since 2022 and was appointed chairman of the Bausch + Lomb Board in August 2026, will continue leading Bausch Health while assuming this role. Brent Saunders, CEO since 2023, departed following a mutual agreement with the Board. Based on preliminary third-quarter results, both companies expect to raise full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D. Specific details regarding the updated financial outlook will be provided when the companies report their third-quarter results on October 28, 2026.